Lundbeck CEO: Alder Buy Will Boost Pipeline

 
• By Sten Stovall
  
Road_Sign
$1.95bn cash acquisition of Alder sees Lundbeck gain eptinezumab to treat migraines. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business